<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[TRIGR Therapeutics, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=33026></link><description><![CDATA[TRIGR Therapeutics, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 29 Apr 2026 21:02:56 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/05/12_3698601005_20190514084108_1100611638.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[TRIGR Therapeutics Announces Formation of Global Clinical & Scientific Advisory Board]]></title><link>https://www.newswire.co.kr/newsRead.php?no=888072</link><description><![CDATA[IRVINE, CA--(Korea Newswire)--TRIGR Therapeutics, Inc. (“TRIGR”), a clinical stage biotechnology company focused on the development of multi-targeted and immunomodulatory bispecific antibodies, announced today the formation of its global Clinical and Scientific Advisory Board (CSAB) comprising of 10 key appointments.  The CSAB will work closely with TRIGR‘s leadership team a...]]></description><pubDate>Tue, 14 May 2019 08:50:17 +0900</pubDate></item></channel></rss>